The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases
1 other identifier
observational
250,000
1 country
1
Brief Summary
Objectives and aim: To evaluate the long-term spill-over (indirect) effect of Coronavirus disease (COVID-19) on health outcomes and healthcare utilization among people with non-communicable diseases and without COVID-19. Design: A population-based cohort study using electronic health records of the Hospital Authority (HA) clinical management system, economic modeling, and serial cross-sectional surveys on healthcare service utilization. Setting: HA public hospitals and outpatient clinics in Hong Kong Participants: People aged ≥ 18 years with a documented diagnosis of diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic respiratory disease, and chronic kidney disease; without COVID-19; attending HA services between 2010 and 2024. Main outcome measures: All-cause mortality, disease-specific outcomes, healthcare service utilization, and costs. Methods: The annual incidence of each outcome in each year between 2010 and 2024 will be calculated. An interrupted time-series analysis to assess the changes in outcomes between pre-and-post-COVID-19 outbreak periods. Long term health economic impact of healthcare disruptions during the COVID-19 outbreak will be modeled using microsimulation. Multivariable Cox proportional hazards regression and Poisson/negative binomial regression to evaluate the effect of different modes of care on the risk of the outcomes. Implications: Findings will inform policies and practices on contingency care plans to avoid excessive morbidity and mortality and to assure the quality of care for patients with NCD as part of the territorial response to the health crisis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 21, 2021
CompletedFirst Submitted
Initial submission to the registry
February 17, 2022
CompletedFirst Posted
Study publicly available on registry
February 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
ExpectedMarch 8, 2022
February 1, 2022
1 year
February 17, 2022
February 20, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Health outcomes
Incidence of all-cause mortality, and disease-specific complications (cardiovascular disease, end-stage renal disease, retinopathy, neuropathy and all-cause mortality) The disease are defined by the diagnosis codes International Classification of Primary Care, Second edition or International Classification of Diseases,Ninth Revision, Clinical Modification.
5 years
Secondary Outcomes (1)
Healthcare service utilization
5 years
Other Outcomes (1)
Burden of diseases due to indirect effect of COVID-19
5 years
Interventions
The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
Eligibility Criteria
* People aged 18 years or above with documented doctor-diagnosed NCDs (diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic kidney disease, or chronic respiratory disease). * People who attended at least once HA hospitals, general or specialist out-patients clinics during the study period.
You may qualify if:
- People aged 18 years or above with a documented doctor-diagnosed NCDs (diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic kidney disease, or chronic respiratory disease )
- People who attended at least once HA hospitals, general or specialist out-patients clinics between 1 January 2010 and 31 December 2024
You may not qualify if:
- \- People with a documented doctor-diagnosed COVID-19
- (For cross-sectional study)
- People aged 18 years or above with a documented doctor-diagnosed NCDs (diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic kidney disease, or chronic respiratory disease )
- All participants are able to communicate in either Chinese or English and provide informed consent.
- People with a documented diagnosis of COVID-19 during the study period.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Family Medicine & Primary Care, LKS Faculty of Medicine, University of Hong Kong
Hong Kong, Hong Kong, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cindy L.K. Lam, MD
The University of Hong Kong
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor, Chairperson of Department of Family Medicine & Primary Care
Study Record Dates
First Submitted
February 17, 2022
First Posted
February 21, 2022
Study Start
June 21, 2021
Primary Completion
June 30, 2022
Study Completion (Estimated)
June 30, 2026
Last Updated
March 8, 2022
Record last verified: 2022-02